Cytochrome P450 pathway contributes to methanandamide-induced vasorelaxation in rat aorta

Cardiovascular Drugs and Therapy

Volumn 24, Issue 5-6, 2010, Pages 379-389

  López Miranda, Visitación ^a   Dannert, M Teresa ^b   Herradón, Esperanza ^a   Alsasua, Angela ^b   Martín, M Isabel ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cytochrome P450 epoxygenase pathway; Methanandamide; Rat aorta; Vasorelaxation

Indexed keywords

CALCIUM ION; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYTOCHROME P450; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; METHANANDAMIDE; POTASSIUM ION; PROSTACYCLIN;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

ANIMALS; AORTA; ARACHIDONIC ACIDS; BIOLOGICAL FACTORS; CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GUANYLATE CYCLASE; MALE; NITRIC OXIDE; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; VASODILATION;

EID: 79958212495     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-010-6261-9     Document Type: Article

References (46)

1. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:31-85.
2. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol. 2007;292:C996-C1012. (Pubitemid 46442641)
3. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res. 2004;49:525-33. (Pubitemid 38338662)
4. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 1996;94:3341-7. (Pubitemid 26427507)
5. Hercule HC, Schunck WH, Gross V, et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol. 2009;29:54-60.
6. Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res. 2009;50:S52-6.
7. Kunos G, Járai Z, Bátkai S, et al. Endocannabinoids as cardiovascular modulators. Chem Phys Lipids. 2000;108:159-68.
8. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther. 2002;95:191-202. (Pubitemid 35232137)
9. López-Miranda V, Herradón E, Martín MI. Vasorelaxation caused by cannabinoids: mechanisms in different vascular beds. Curr Vasc Pharmacol. 2008;6:335-46.
10. Dannert MT, Alsasua A, Herradón E, Martín MI, López-Miranda V. Vasorelaxant effect of Win 55, 212-2 in rat aorta: new mechanisms involved. Vascul Pharmacol. 2007;46:16-23. (Pubitemid 44856374)
11. Herradón E, Martín MI, López-Miranda V. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol. 2007;152:699-708. (Pubitemid 350034972)
12. Grainger J, Boachie-Ansah G. Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol. 2001;134:1003-12. (Pubitemid 33052159)
13. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature. 2003;424:434-8. (Pubitemid 36917492)
14. Ho WSV, Randall MD. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol. 2007;150:641-51. (Pubitemid 46355564)
15. Kozłowska H, Baranowska M, Schlicker E, Kozłowski M, Laudañski J, Malinowska B. Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br J Pharmacol. 2008;155:1034-42.
16. Lake KD, Compton DR, Varga K, Martin BR, Kunos G. Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther. 1997;281:1030-7. (Pubitemid 27258357)
17. Malinowska B, Kwolek G, Göthert M. Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptormediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn-Schmiedeberg's Arch Pharmacol. 2001;364:562-9. (Pubitemid 33145097)
18. Wang Y, Kaminski NE, Wang DH. VR1-mediated depressor effects during high-salt intake: role of anandamide. Hypertension. 2005;46:986-91.
19. Vanheel B, Van de Voorde J. Regional differences in anandamide-and methanandamide-induced membrane potential changes in rat mesenteric arteries. J Pharmacol Exp Ther. 2001;296:322-8. (Pubitemid 32112456)
20. Breyne J, Vanheel B. Methanandamide hyperpolarizes gastric arteries by stimulation of TRPV1 receptors on perivascular CGRP containing nerves. J Cardiovasc Pharmacol. 2006;47:303-9. (Pubitemid 44384070)
21. Sade H, Muraki K, Ohya S, Hatano N, Imaizumi Y. Activation of large-conductance, Ca2+-activated K+ channels by cannabinoids. Am J Physiol Cell Physiol. 2006;290:C77-86.
22. López-Miranda V, Herradón E, Dannert MT, Alsasua A, Martín MI. Anandamide vehicles: a comparative study. Eur J Pharmacol. 2004;505:151-61. (Pubitemid 39535687)
23. 2+ exchanger-mediated vasoconstriction in rat aorta. Br J Pharmacol. 2008;154:982-90.
24. Van der Zypp A, Kang KB, Majewski H. Age-related involvement of the endothelium in b-adrenoceptor-mediated relaxation of rat aorta. Eur J Pharmacol. 2000;397:129-38. (Pubitemid 30323819)
25. Woodman OL, Malakul W. 3′, 4′-Dihydroxyflavonol prevents diabetes-induced endothelial dysfunction in rat aorta. Life Sci. 2009;85:54-9.
26. Wagner JA, Varga K, Jarai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 1999;33:429-34. (Pubitemid 29065697)
27. Wagner JA, Jarai Z, Bátkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol. 2001;423:203-10. (Pubitemid 32614159)
28. Ralevic V, Kendall DA, Zygmunt PM, Movahed P, Högestätt ED. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed. Br J Pharmacol. 2000;130:1483-8.
29. Breyne J, Van de Voorde J, Vanheel B. Characterization of the vasorelaxation to methanandamide in rat gastric arteries. Can J Physiol Pharmacol. 2006;84:1121-32. (Pubitemid 46465924)
30. Mukhopadhyay S, Chapnick BM, Howlett AC. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol. 2002;282:H2046-54.
31. Randall MD, Kendall DA, O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol. 2004;142:20-6. (Pubitemid 38698188)
32. Mukhopadhyay S, Howlett AC. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol. 2005;67:2016-24. (Pubitemid 41007783)
33. Wagner JA, Abesser M, Karcher J, Laser M, Kunos G. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J Cardiovasc Pharmacol. 2005;46:348-55. (Pubitemid 41262838)
34. 2 receptors. Proc Natl Acad Sci USA. 1999;96:14136-41.
35. Mendizabal VE, Orliac ML, Adler-Graschinsky E. Long-term inhibition of nitric oxide synthase potentiates effects of anandamide in the rat mesenteric bed. Eur J Pharmacol. 2001;427:251-62. (Pubitemid 32913293)
36. Högestätt ED, Zygmung PM. Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids. 2002;66:343-51. (Pubitemid 34743607)
37. Poblete IM, Orliac ML, Briones R, Adler-Graschinsky E, Huidobro-Toro JP. Anandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bed. J Physiol. 2005;568:539-51. (Pubitemid 41555456)
38. McCollum L, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther. 2007;321:930-7. (Pubitemid 46762688)
39. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem. 2007;282:2891-8. (Pubitemid 47084334)
40. 2+ sparks as elementary physiological events. Circ Res. 1998;83:1104-14.
41. Lohn M, Jessner W, Furstenau M, et al. Regulation of calcium sparks and spontaneous transient outward currents by RyR3 in arterial vascular smooth muscle cells. Circ Res. 2001;89: 1051-7. (Pubitemid 34640873)
42. Félétou M. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options? Br J Pharmacol. 2009;156:545-62.
43. Busse R, Edward G, Félétou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002;23:374-80.
44. Félétou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol. 2006;26:1215-25.
45. 2+ and other cellular metabolites. Gen Pharmacol. 1999;33:325-36.
46. Chen JK, Chen J, Imig JD, et al. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J Biol Chem. 2008;283:24514-24.